# US 2025/0059273 A1 · Humanized non-opioid composition and therapies for pain management

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0059273 A1
- Document ID: US20250059273A1
- Status: Published application
- Kind: A1
- Application number: 18/720,191
- Filed: 2022-12-16
- Published: 2025-02-20
- Earliest claimed: 2021-12-16
- Assignees: UNM Rainforest Innovations; Mayo Foundation for Medical Education and Research
- Applicants: UNM Rainforest Innovations; Mayo Foundation for Medical Education and Research
- Inventors: Karin Westlund High; Adinarayana Kunamneni
- Web page: https://patentgrep.com/patent/US20250059273A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- C12N 15/86: Viral vectors
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A humanized anti-human P2X4R antibody, or an antigen binding fragment thereof, or a polypeptide, that inhibits human P2X4R activity, is provided as well as methods of making and using the antibody or an antigen binding fragment thereof.

## Claims

### Claim 1

A composition comprising a humanized anti-human P2X4R antibody, or an antigen binding fragment thereof, or a polypeptide, that inhibits human P2X4R activity, wherein the antibody, the antigen binding fragment thereof, or the polypeptide has:
i) a variable region comprising a first complementarity determining region (CDR) comprising GFTFTDYY (SEQ ID NO:1) operably linked to a second CDR comprising IRNKANGYTT (SEQ ID NO:2) operably linked to a third CDR comprising ARWEGDLLYAMDY (SEQ ID NO:3); and/or
ii) a variable region comprising a first CDR comprising QGISNY (SEQ ID NO:4) operably linked to a second CDR comprising YTS operably linked to a third CDR comprising QQYSKLPWT (SEQ ID NO:6).

### Claim 2 (depends on 2)

The composition of claim 2 wherein the antibody is a scFv.

### Claim 3

An isolated cell comprising an expression cassette comprising a heterologous promoter operably linked to nucleic acid sequences encoding a humanized anti-human P2X4R antibody, or an antigen binding fragment thereof, or a polypeptide, that inhibits human P2X4R activity, wherein the antibody, the antigen binding fragment thereof, or the polypeptide has:
i) a variable region comprising a first complementarity determining region (CDR) comprising GFTFTDYY (SEQ ID NO:1) operably linked to a second CDR comprising IRNKANGYTT (SEQ ID NO:2) operably linked to a third CDR comprising ARWEGDLLYAMDY (SEQ ID NO:3); and/or
ii) a variable region comprising a first CDR comprising QGISNY (SEQ ID NO:4) operably linked to a second CDR comprising YTS operably linked to a third CDR comprising QQYSKLPWT (SEQ ID NO:6).

### Claim 4 (depends on 3)

The cell of claim 3 which is a mammalian cell.

### Claim 5 (depends on 3)

The cell of claim 3 wherein the cell is a primate cell.

### Claim 6 (depends on 3)

The cell of claim 3 wherein the cell is a human cell.

### Claim 7

An isolated nucleic acid comprising a nucleotide sequence which encodes at least the variable region of a human heavy or light chain that binds human P2X4R, wherein the chain comprises:
i) a variable region comprising a first complementarity determining region (CDR) comprising GFTFTDYY (SEQ ID NO:1) operably linked to a second CDR comprising IRNKANGYTT (SEQ ID NO:2) operably linked to a third CDR comprising ARWEGDLLYAMDY (SEQ ID NO:3); and/or
ii) a variable region comprising a first CDR comprising QGISNY (SEQ ID NO:4) operably linked to a second CDR comprising YTS operably linked to a third CDR comprising QQYSKLPWT (SEQ ID NO:6).

### Claim 8

A method to inhibit or treat depression, [or] anxiety or pain in a mammal, comprising: administering to a mammal a composition comprising an effective amount of a nucleotide sequence which encodes at least the variable region of a human heavy or light chain that binds human P2X4R, or an effective amount of an isolated polypeptide having at least the variable region of a human heavy or light chain that binds human P2X4R, wherein the chain comprises:
i) a variable region comprising a first complementarity determining region (CDR) comprising GFTFTDYY (SEQ ID NO:1) operably linked to a second CDR comprising IRNKANGYTT (SEQ ID NO:2) operably linked to a third CDR comprising ARWEGDLLYAMDY (SEQ ID NO:3); and/or
ii) a variable region comprising a first CDR comprising QGISNY (SEQ ID NO:4) operably linked to a second CDR comprising YTS operably linked to a third CDR comprising QQYSKLPWT (SEQ ID NO:6), or
an antibody or fragment comprising
i) a variable region comprising a first complementarity determining region (CDR) comprising GFTFTDYY (SEQ ID NO:1) operably linked to a second CDR comprising IRNKANGYTT (SEQ ID NO:2) operably linked to a third CDR comprising ARWEGDLLYAMDY (SEQ ID NO:3); and/or
ii) a variable region comprising a first CDR comprising QGISNY (SEQ ID NO:4) operably linked to a second CDR comprising YTS operably linked to a third CDR comprising QQYSKLPWT (SEQ ID NO:6).

### Claim 9 (depends on 8)

The method of claim 8 wherein the heavy chain is an IgG heavy chain.

### Claim 10 (depends on 8)

The method of claim 8 wherein the light chain is an IgK light chain.

### Claim 11 (depends on 8)

The method of claim 8 wherein the antibody fragment is administered.

### Claim 12 (depends on 11)

The method of claim 11 wherein the fragment is Fab′ or scFv.

### Claim 13

(canceled)

### Claim 14 (depends on 8)

The method of claim 8 wherein the mammal has neuropathic pain.

### Claim 15 (depends on 8)

The method of claim 8 wherein the mammal was exposed to blunt force trauma.

### Claim 16 (depends on 8)

The method of claim 8 wherein the mammal has traumatic brain injury.

### Claim 17 (depends on 8)

The method of claim 8 wherein the mammal is a human.

### Claim 18 (depends on 8)

The method of claim 8 wherein the composition is systemically administered.

### Claim 19 (depends on 8)

The method of claim 8 wherein the composition is injected.

### Claim 20 (depends on 8)

The method of claim 8 wherein the composition is subcutaneously administered.

### Claim 21 (depends on 8)

The method of claim 8 wherein the composition is intranasally administered.

### Claim 22 (depends on 8)

The method of claim 8 wherein the nucleotide sequence is in a viral vector.

### Claim 23 (depends on 22)

The method of claim 22 wherein the viral vector is an AAV, lentiviral or retroviral vector.
